ストックスクリーナーアプリを入手
0.586
5.48%
-0.034
前日終値:
$0.62
開ける：
$0.62
24時間の取引高:
13,257
Relative Volume:
0.18
時価総額：
$10.88M
収益：
$2.82M
当期純損益:
$-14.20M
株価収益率:
-0.6894
EPS:
-0.85
ネットキャッシュフロー:
$-15.13M
1週間 パフォーマンス:
-7.67%
1か月 パフォーマンス:
+1.40%
6か月 パフォーマンス:
-31.78%
1年 パフォーマンス:
-43.11%
1日の値動き範囲:
$0.586
$0.62
1週間の範囲:
$0.586
$0.655
52週間の値動き範囲:
$0.501
$1.27
Talphera Inc Stock (TLPH) Company Profile
TLPH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.586 | 10.88M | 2.82M | -14.20M | -15.13M | -0.85 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.81 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2020-07-20 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2019-11-11 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-05 | 再開されました | Credit Suisse | Outperform |
| 2019-07-10 | 再開されました | Credit Suisse | Outperform |
| 2019-04-24 | 再開されました | B. Riley FBR | Buy |
| 2019-02-15 | 開始されました | Credit Suisse | Outperform |
| 2018-10-23 | 開始されました | B. Riley FBR | Buy |
| 2017-10-13 | ダウングレード | Jefferies | Buy → Hold |
| 2017-10-13 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-07-14 | 再開されました | Jefferies | Buy |
| 2016-09-15 | 繰り返されました | ROTH Capital | Buy |
| 2016-08-05 | ダウングレード | Stifel | Buy → Hold |
| 2015-10-30 | アップグレード | Jefferies | Hold → Buy |
| 2015-10-05 | 繰り返されました | ROTH Capital | Buy |
| 2015-09-02 | 開始されました | H.C. Wainwright | Buy |
| 2015-07-10 | 再開されました | ROTH Capital | Buy |
| 2015-05-06 | 繰り返されました | Mizuho | Neutral |
| 2015-05-05 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-03-10 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-03-09 | ダウングレード | Mizuho | Buy → Neutral |
すべてを表示
Talphera Inc (TLPH) 最新ニュース
Earnings Outlook For Talphera - Benzinga
Talphera to Unveil 2024 Performance: Key Financial Results and Strategic Updates Coming March 31 - StockTitan
Talphera Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Talphera (TLPH) Expected to Announce Earnings on Wednesday - Defense World
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock By Investing.com - Investing.com South Africa
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock - Investing.com
Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened - Armenian Reporter
Talphera Inc (NASDAQ: TLPH) Is On The Rise - Stocks Register
RODMAN&RENSHAW Upgrades Talphera (NASDAQ:TLPH) to Strong-Buy - Defense World
Rodman & Renshaw sets Talphera stock Buy rating, $4 target - MSN
Talphera (NASDAQ:TLPH) Receives “Buy” Rating from HC Wainwright - Defense World
FDA to review Talphera's request to amend NEPHRO study By Investing.com - Investing.com Canada
FDA to review Talphera’s request to amend NEPHRO study By Investing.com - Investing.com Nigeria
FDA to review Talphera's request to amend NEPHRO study - Investing.com
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study - The Eastern Progress Online
TLPH stock touches 52-week low at $0.6 amid market shifts - Investing.com UK
TLPH stock touches 52-week low at $0.61 amid market challenges - Investing.com
Talphera faces Nasdaq delisting over share price rule - Investing.com
Talphera faces Nasdaq delisting over share price rule By Investing.com - Investing.com UK
Acelrx Announces Dsuvia® Milestone C Approval; Provides Revenue Guidance for the First Quarter 2020 - Marketscreener.com
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024 - Kilgore News Herald
Talphera CEO Vincent J. Angotti acquires $3,199 in common stock - Investing.com
Talphera CEO Vincent J. Angotti acquires $3,199 in common stock By Investing.com - Investing.com UK
Talphera CEO Vincent J. Angotti buys $3,649 in company stock By Investing.com - Investing.com Canada
Talphera CFO Raffi Asadorian sells shares worth $118 - Investing.com India
Talphera CEO Vincent J. Angotti buys $3,649 in company stock - Investing.com India
Talphera CFO Raffi Asadorian sells shares worth $118 By Investing.com - Investing.com Canada
Talphera Third Quarter 2024 Earnings: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023) - Yahoo Finance
Talphera (FRA:R5XA) Inventories, Raw Materials & Components : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - Yahoo Finance
Talphera: Q3 Earnings Snapshot - mySA
Talphera Reports Q3 2024 Results and Study Progress - TipRanks
Talphera's Q3 Loss Widens to $3.4M as NEPHRO Trial Expands to New Sites | TLPH Stock News - StockTitan
An Overview of Talphera's Earnings - Benzinga
Talphera Sets Q3 2024 Earnings Call for November 13Key Financial Results Update | TLPH Stock News - StockTitan
Talphera, Inc. (NASDAQ:TLPH) Sees Large Decline in Short Interest - Defense World
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - Citizentribune
Talphera extends agreement deadline with Nantahala Management By Investing.com - Investing.com Australia
Talphera extends agreement deadline with Nantahala Management - Investing.com
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - PR Newswire
Talphera CEO Vincent J. Angotti buys $7.6k in company stock - Investing.com
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit - PR Newswire
Talphera First Half 2024 Earnings: US$0.31 loss per share (vs US$0.40 loss in 1H 2023) - Yahoo Finance
Talphera Announces CMO Retirement and Successor Appointment - TipRanks
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
Talphera Inc (TLPH) 財務データ
収益
当期純利益
現金流量
EPS
Talphera Inc (TLPH) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Aslam Shakil | Chief Medical Officer |
Jun 13 '24 |
Buy |
0.98 |
695 |
681 |
32,695 |
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Dec 05 '24 |
Buy |
0.64 |
5,000 |
3,200 |
208,066 |
| ASADORIAN RAFFI | Chief Financial Officer |
Dec 02 '24 |
Sale |
0.77 |
155 |
119 |
37,578 |
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Nov 27 '24 |
Buy |
0.73 |
5,000 |
3,650 |
203,066 |
3.70%
0.05%
大文字化:
|
ボリューム (24 時間):